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W
e thank Conway et al. (1) for the
discussion of their ﬁndings re-
garding skin intrinsic ﬂuores-
cence in the Pittsburgh Epidemiology of
Diabetes Complications (EDC) study co-
hort. Their results—that skin intrinsic
ﬂuorescence values are higher in individ-
uals with no diabetic retinopathy (DR) as
compared with more advanced DR—are
consistent with our ﬁndings in the Med-
alistcohortinwhichincreasedconcentra-
tions of certain advanced glycation end
products (carboxymethyl-lysine [CML]
and the early glycation product fructose-
lysine in the Medalists) were associated
with protection from proliferative DR.
Our ﬁndings of an inverse relationship
between CML levels and proliferative ret-
inopathy may suggest low levels of endo-
thelial or inﬂammatory cell receptor for
advanced glycation end product expres-
sion or activation (2) in response to its
ligand CML in these participants.
In contrast to the Medalist group in
which no difference in glycemic control
was found between those with and with-
outproliferativeDR,theEDCparticipants
without DR had better glycemic control
than those with DR. This difference may
reﬂect the fact that the EDC population
had a shorter average duration of diabetes
than the Medalists (41 vs. 57 years) and
thus may have a lower percentage of par-
ticipants with elevated protective factors
against complications. Nonetheless, this
report further conﬁrms the existence of a
subgroup of individuals who appear to be
highly protected against the detrimental
effects of chronic hyperglycemia and sup-
ports additional characterization of this
unique population in hopes of identifying
novel protective factors against retinopa-
thy and other microvascular complica-
tions of diabetes.
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